EverSource Wealth Advisors LLC Sells 180 Shares of Zoetis Inc. (NYSE:ZTS)

EverSource Wealth Advisors LLC cut its stake in shares of Zoetis Inc. (NYSE:ZTS) by 9.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,663 shares of the company’s stock after selling 180 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Zoetis were worth $271,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Callahan Advisors LLC raised its position in shares of Zoetis by 90.4% during the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after purchasing an additional 6,221 shares during the period. Pensionfund Sabic raised its holdings in Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after acquiring an additional 4,000 shares during the period. CIBC Asset Management Inc lifted its position in shares of Zoetis by 24.1% in the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock valued at $38,617,000 after acquiring an additional 46,050 shares in the last quarter. PFW Advisors LLC bought a new position in shares of Zoetis in the fourth quarter worth about $1,764,000. Finally, Alberta Investment Management Corp grew its position in shares of Zoetis by 2,050.0% during the fourth quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock worth $4,904,000 after purchasing an additional 28,700 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. This trade represents a 9.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. This represents a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is currently owned by insiders.

Zoetis Trading Up 0.8 %

Shares of ZTS opened at $161.33 on Friday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The company’s fifty day simple moving average is $166.82 and its 200-day simple moving average is $176.15. The company has a market cap of $72.24 billion, a P/E ratio of 29.49, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. As a group, analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.24%. Zoetis’s payout ratio is 36.56%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Stifel Nicolaus dropped their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. UBS Group started coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective on the stock. Finally, Morgan Stanley lowered their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zoetis has an average rating of “Buy” and an average target price of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.